Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists

Jacob Abraham1, James O Mudd, Navin K Kapur

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Insights

Intravenous catecholamines and beta-receptor agonists can trigger stress cardiomyopathy, a condition of reversible heart dysfunction. This study highlights the role of excessive sympathetic stimulation in this cardiac syndrome.

Area of Science:

  • Cardiology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Stress cardiomyopathy, a transient cardiac dysfunction, is linked to intense stress and sympathetic overstimulation.
  • The direct causal link between sympathetic stimulation and stress cardiomyopathy remains unclear.

Purpose of the Study:

  • To investigate stress cardiomyopathy precipitated by intravenous catecholamines and beta-receptor agonists.
  • To establish a causal link between sympathetic stimulation and stress cardiomyopathy.

Main Methods:

  • Observational study of 9 patients who developed stress cardiomyopathy after epinephrine or dobutamine administration.
  • Evaluation included coronary angiography, echocardiography, electrocardiography, and cardiac enzymes.

Main Results:

  • All patients showed QTc interval prolongation and elevated troponin-I without obstructive coronary disease.
  • Left ventricular dysfunction, including various "ballooning" patterns, was observed with a median ejection fraction of 35% on admission.
  • Complete recovery of left ventricular systolic function was noted within a median of 7 days.

Conclusions:

  • Catecholamines and beta-receptor agonists can precipitate stress cardiomyopathy, mimicking its key features.
  • These findings strongly suggest excessive sympathetic stimulation is central to the pathogenesis of stress cardiomyopathy.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...